Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dengue subunit vaccine - Merck Sharp and Dohme

Drug Profile

Dengue subunit vaccine - Merck Sharp and Dohme

Alternative Names: DEN 1 80E; Dengue subunit vaccine - Hawaii Biotech; HB6; HBV-001 D1; Tetravalent dengue vaccine - Merck Sharp & Dohme; V 180

Latest Information Update: 28 Mar 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hawaii Biotech
  • Developer Merck Sharp & Dohme; National Institute of Allergy and Infectious Diseases
  • Class Dengue vaccines; Subunit vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Dengue

Most Recent Events

  • 28 Mar 2022 No recent reports of development identified for phase-I development in Dengue(In volunteers) in Australia (IM, Injection)
  • 28 Mar 2022 No recent reports of development identified for phase-I development in Dengue(In volunteers) in USA (IM, Injection)
  • 27 Feb 2020 Phase-I development is ongoing in Dengue in Australia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top